PDS Biotechnology Corp Announces FDA Approval of IND Application for VERSAMUNE® MUC1 and PDS01ADC Combination

Summary

On March 13, PDS Biotechnology Corp announced that the FDA approved its IND application for the combined use of Versamune® MUC1 and PDS01ADC for treating metastatic colorectal cancer.Reuters

Impact Analysis

This company-level event indicates progress in PDS Biotechnology Corp’s product pipeline, potentially increasing investor confidence and attracting interest in its stock. The FDA approval can lead to increased valuation and investment opportunities in the biotech sector, particularly for those focused on cancer treatment innovations.Reuters